П

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| Check this box if no longer subject to |
|--|
| Section 16. Form 4 or Form 5 |
| obligations may continue. See |
| Instruction 1(b). |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| OMB APPROVAL | | | | | | | | | |
|--------------------------|-----------|--|--|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | | | |
| Estimated average burden | | | | | | | | | |
| hours per response: | 0.5 | | | | | | | | |

| (Last) (First) (Middle) | | n* | 2. Issuer Name and Ticker or Trading Symbol <u>REGENERON PHARMACEUTICALS</u> <u>INC</u> [REGN] | | tionship of Reporting Perso all applicable) Director Officer (give title | 10% Owner Other (specify |
|---------------------------------|---------------|----------------|--|------------------------|--|-----------------------------|
| | | , | 3. Date of Earliest Transaction (Month/Day/Year) 06/10/2013 | | below) | below) |
| (Street) TARRYTOWN (City) | NY (State) | 10591 (Zip) | 4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Indiv Line) X | idual or Joint/Group Filing (Form filed by One Report Form filed by More than C Person | ing Person |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | | | | | 5. Amount of Securities Beneficially Owned Following Reported | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership |
|---------------------------------|--|---|---|---|--------|---------------|---------------------------------|---|---|---|
| | | | Code | v | Amount | (A) or (D) | Price | Transaction(s) (Instr. 3 and 4) | | (Instr. 4) |
| Common Stock | 06/10/2013 | | M ⁽¹⁾ | | 15,000 | A | \$15.8 | 24,000 | D | |
| Common Stock | 06/10/2013 | | S ⁽¹⁾ | | 4,150 | D | \$250.06(2) | 19,850 | D | |
| Common Stock | 06/10/2013 | | S ⁽¹⁾ | | 3,938 | D | \$251.67 ⁽³⁾ | 15,912 | D | |
| Common Stock | 06/10/2013 | | S ⁽¹⁾ | | 4,748 | D | \$ 252.32 ⁽⁴⁾ | 11,164 | D | |
| Common Stock | 06/10/2013 | | S ⁽¹⁾ | | 908 | D | \$253.5 ⁽⁵⁾ | 10,256 | D | |
| Common Stock | 06/10/2013 | | S ⁽¹⁾ | | 756 | D | \$254.1 ⁽⁶⁾ | 9,500 | D | |
| Common Stock | 06/10/2013 | | S ⁽¹⁾ | | 200 | D | \$255.16 | 9,300 | D | |
| Common Stock | 06/10/2013 | | S ⁽¹⁾ | | 300 | D | \$257.99(7) | 9,000 | D | |
| Common Stock | | | | | | | | 590 | Ι | by Partnershi |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transa Code (8) | | of | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---|---|--|---|------------------------------|---|-----|--------|--|--------------------|---|--|---|--|--|--|
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | |
| Non- Qualified Stock Option (right to buy) | \$15.8 | 06/10/2013 | | M ⁽¹⁾ | | | 15,000 | (8) | 01/03/2016 | Common Stock | 15,000 | (9) | 0 | D | |

Explanation of Responses:

1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

2. Represents volume-weighted average price of sales of 4,150 shares of Company stock on June 10, 2013 at prices ranging from \$250.00 to \$250.78. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 10, 2013 at each separate price.

3. Represents volume-weighted average price of sales of 3,938 shares of Company stock on June 10, 2013 at prices ranging from \$251.15 to \$251.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 10, 2013 at each separate price.

4. Represents volume-weighted average price of sales of 4,748 shares of Company stock on June 10, 2013 at prices ranging from \$252.00 to \$252.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 10, 2013 at each separate price.

5. Represents volume-weighted average price of sales of 908 shares of Company stock on June 10, 2013 at prices ranging from \$253.11 to \$253.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 10, 2013 at each separate price.

6. Represents volume-weighted average price of sales of 756 shares of Company stock on June 10, 2013 at prices ranging from \$254.04 to \$254.23. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 10, 2013 at each separate price.

Represents volume-weighted average price of sales of 300 shares of Company stock on June 10, 2013 at prices ranging from \$257.98 to \$257.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 10, 2013 at each separate price.
 The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.

o. The stock option becomes exercisable in unee equal annual instantients, commencing one year after the date of grant.

9. Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case

/s/**Charles A. Baker 06/11/2013

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.